Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘chemotherapy’

Chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia

Posted by fidest press agency su giovedì, 12 dicembre 2019

Basel. Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data from two pivotal phase III Venclexta®/Venclyxto® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta/Venclyxto combination treatments as chemotherapy-free, fixed-duration options that achieve minimal residual disease (MRD)-negativity, in people with chronic lymphocytic leukaemia (CLL). These data and others from the Venclexta/Venclyxto clinical development programme will be featured in more than 50 abstracts at the 61st American Society of Hematology (ASH) Annual Meeting.“Venclexta/Venclyxto plus anti-CD20 monoclonal antibody-based regimens continue to demonstrate improved long-term outcomes for people with chronic lymphocytic leukaemia,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “These results reinforce the sustained clinical benefits observed in patients with this common type of blood cancer, after completing this fixed-duration, chemotherapy-free treatment.”
The pivotal phase III CLL14 study evaluated the combination of Venclexta/Venclyxto plus Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated CLL, who had co-existing medical conditions. At a median follow-up of more than three years (39.57 months), when all patients had been off therapy for a minimum of two years, Venclexta/Venclyxto plus Gazyva/Gazyvaro showed high response rates, including MRD-negativity. Specifically:Higher rates of MRD-negativity in peripheral blood (76% vs. 35%; p<0.001) and bone marrow (57% vs. 17; p<0.001%) were observed at the end of treatment in people treated with Venclexta/Venclyxto plus Gazyva/Gazyvaro versus Gazyva/Gazyvaro plus chlorambucil, respectively. MRD-negativity indicates that no cancer can be detected using a specific, highly sensitive test, and was defined as less than one CLL cell in 10,000 white blood cells.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Susan G. Komen Statement on TAILORx Study Citing Chemotherapy Not Needed for Some Breast Cancer Patients

Posted by fidest press agency su martedì, 5 giugno 2018

Susan G. Komen®, the world’s leading breast cancer organization, issued the following statement regarding a new study partially funded by the organization – called Trial Assigning Individualized Options for Treatment, or TAILORx. The study shows that many women with early stage breast cancer may not need to undergo chemotherapy treatment. The study was published today in the New England Journal of Medicine and presented this weekend at a meeting of the American Society of Clinical Oncology.
The study found that 70 percent of women with early stage breast cancers that are HER2 negative and are sensitive to estrogen, may be able to forgo chemotherapy and its toxic side effects. By using individuals’ Oncotype DX Genomic testing score, researchers found some patients need take only hormone therapy, drugs that block the hormone estrogen or stops the body from making it. This statement can be attributed to Victoria Wolodzko, Komen’s Senior Vice President of Mission.
“Susan G. Komen has been concerned for years about the toxic side effects of chemotherapy, because while it can save lives, it also can potentially cause heart and nerve damage, and also leave patients vulnerable to infection and increase the risk of leukemia later in life. This is why we have funded a body of research that seeks to more precisely treat breast cancers and potentially avoid chemotherapy. This study, which was supported in part by Komen funding, suggests that we have the potential to use Genomic testing to tell some women more precisely whether they would benefit from chemotherapy or not.”According to the researchers, the study definitively identifies the 70% of women with early-stage, hormone-receptor positive, HER-2 negative, node-negative breast cancer who do not benefit from chemotherapy and the 30% of those women for whom chemotherapy can be lifesaving. For all women who fall in the mid-range of Oncotype Dx test scores regardless of age, there was a clear and large chemotherapy benefit. In women younger than 50, those with lower scores showed modest (2%) chemotherapy benefit, which gradually grew as scores increased. This important finding reveals how Oncotype DX testing can lead to a new level of precision treatment.The TAILORx trial was independently designed and conducted by ECOG-ACRIN under the sponsorship of the National Cancer Institute (NCI), and was the largest adjuvant breast cancer treatment trial ever conducted. It enrolled 10,273 women with early-stage breast cancer across approximately 1,200 sites in the United States and 5 additional countries. Komen funded Dr. Joseph A. Sparano of Montefiore Medical Center in New York, the leader of the study, to create a biospecimen bank focused on defining tumor and host factors contributing to recurrence of breast cancer occurring more than five years after diagnosis.Komen has invested more than $266 million in over 590 research grants and nearly 100 clinical trials focused on precision medicine.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Do men have worse chemotherapy-induced cardiomyopathy than women?

Posted by fidest press agency su giovedì, 25 maggio 2017

Praga, Stare Mesto 1983, mostra Jappelli 01Prague, Czech Republic Men seem to have worse chemotherapy-induced cardiomyopathy than women despite receiving similar cancer treatments, according to research presented today at EuroCMR 2017. “Cancer patients are living longer because of improved treatment but the side effects of treatment include cardiovascular morbidity and mortality,” said lead author Dr Iwan Harries, cardiology specialist registrar at Bristol Heart Institute, currently pursuing a PhD on cardiac magnetic resonance (CMR) imaging and cardio-oncology at the University of Bristol, UK.A 2016 European Society of Cardiology (ESC) position paper on cardio-oncology described female sex as a risk factor for developing cardiotoxicity from chemotherapy.2 Dr Harries said: “The data largely originates from paediatric populations and, in contrast, animal studies report male susceptibility to cardiomyopathy.” This retrospective observational study in adults investigated whether there was a sex effect on chemotherapy-induced cardiomyopathy. The researchers identified all patients over a six year period that received potentially cardiotoxic chemotherapy, were referred for CMR, and were found to have impaired left ventricular function (chemotherapy-induced cardiomyopathy). Patients were excluded if they had another condition that could have contributed to the cardiomyopathy such as ischaemic heart disease, valvular heart disease, family history of cardiomyopathy, or excess alcohol consumption. The study included 76 patients (45 women and 31 men). Data was collected on baseline demographics and comorbidities. Details of the cancer treatment were recorded, including the type of chemotherapy, dose of chemotherapy, and the interval between receiving treatment and having the CMR scan. CMR scans provided information on left and right ventricular function, cardiac volumes, and tissue characteristics.To assess the potential impact of gender on the development of chemotherapy-induced cardiomyopathy, the researchers conducted a multivariate regression analysis correcting for baseline differences between men and women including age, body surface area, comorbidities, and treatment.The researchers found that both left and right ventricular ejection fraction was significantly lower in men than women, indicating worse performance of the heart. Cardiac volumes and mass were significantly larger in men compared to women, indicating more damage to the heart’s structure. Dr Harries said: “The results of our study suggest that men developed a more severe form of chemotherapy-induced cardiomyopathy than women at follow-up of 8.75 years. Patients receiving anthracycline received on average 240 mg/m2 of doxorubicin or equivalent, a dose which was similar in both men and women.”
Previous studies in paediatric populations which found increased risk in females may be explained by the absence of female sex hormones early in life. In adults it may be that female sex hormones are protective. “Previous lab-based research has shown that female adult rat cardiac muscle cells have a survival advantage over male cells when challenged with oxidative stress-induced cell death3, which is one of the proposed mechanisms of chemotherapy-induced cardiomyopathy,” Dr Harries explained. Dr Harries said: “Ours is a preliminary result and large scale trials are needed to confirm our finding that men are more susceptible to chemotherapy-induced cardiomyopathy than women. If confirmed, the implication of these findings is that cardiologists and oncologists could devise individualised treatment and monitoring strategies for their patients that take gender into account.” “Cardio-oncology is a new field of cardiology that is rapidly developing thanks to oncology treatments being more efficacious and oncology patients living longer but with associated cardiovascular morbidity and mortality due to cardiotoxicity,” Dr Bucciarelli-Ducci, senior lecturer in cardiology at the University of Bristol and principal investigator of the study concluded.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

‘Cancer Drug Market Will Reach $75 Billion in 2012’ visiongain Report Predicts

Posted by fidest press agency su martedì, 28 febbraio 2012

London (PRNewswire) A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. Visiongain is a business information provider based in London, UK.The new study predicts that overall revenues for anti-cancer treatments will increase strongly from 2012 to 2022. Individual drugs will benefit too. Roche will continue to be the leading company in the cancer-treating drugs market throughout the study’s forecast period. Through emerging technologies and increasing demand in developed and developing countries, the future of cancer treatments holds great promise. That revenue growth will be mainly owing to the worldwide increase in cancer incidence and prevalence. New opportunities for cancer treatment exist, with high sales likely from many drugs – small-molecule products and biological agents (biologicals) – to 2022. Also, R&D pipelines in oncology are strong, including those for monoclonal antibodies (MAbs).The visiongain pharmaceutical industry analyst at visiongain, said, “Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs. There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients’ lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine.”

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Antiretrovirali efficaci sulla funzionalità polmonare

Posted by fidest press agency su sabato, 19 settembre 2009

La terapia antiretrovirale potrebbe ridurre le anormalità polmonari indotte nei pazienti sieropositivi. Secondo una ricerca presentata alla Interscience Conference on Antimicrobial Agents and Chemotherapy a San Francisco, la terapia non solo non presenta alcun rischio per la funzionalità polmonare, ma potrebbe, anzi, avere un effetto benefico. Lo studio ha preso in esame in un follow-up di 4 anni e mezzo, 63 pazienti con Hiv. “La gran parte dei pazienti”- ha spiegato Ulrik Kristoffersen che ha condotto la ricerca – “in terapia antiretrovirale, ha evidenziato un miglioramento della funzione respiratoria, in particolare tra i non fumatori”. Due le principali anormalità polmonari osservate alla partenza dello studio nel 2001: difficoltà nel passaggio di gas dalla parete alveolare al circolo sanguigno, sintomo di infiammazione polmonare, e un aumentato volume residuo nei polmoni, che è indicativo di un danno al tessuto polmonare. Entrambi i parametri al termine dello studio si sono normalizzati nei soggetti in terapia antiretrovirale, in particolare se non fumatori. In prospettiva, sottolinea il responsabile della ricerca, studi longitudinali dovranno considerare test di funzionalità polmonare nella valutazione di pazienti “treatment-naive” in terapia antiretrovirale. (M.M.) Interscience Conference on Antimicrobial Agents and Chemotherapy

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Anticancer agents

Posted by fidest press agency su martedì, 14 aprile 2009

Tubercin Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea. The decisive measure to cope with cancer is surgery. When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells. Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient’s prognosis turns better through a simulative action on immune system of the cancer case. Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from microbacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients. Tubercin is derived from micro bacterium tuberculosis. As an immunostimulant, Tubercin strengthens the human body’s own immune system and assists the body in seeking out and combating cancer cells. HTTD is potentially able to develop Tubercin into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of Tubercin, could positively affect thousands of lives in North America. In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer. Tubercin is a finished product. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer. There have been no indications of any adverse side effects in human trials There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »